Report Archive
All Research
Page 2 of 43 · 1027 reports
52/100
Oracle Corporation
Oracle is an enterprise software and cloud infrastructure vendor whose database and applications cash engine is now funding a massive AI data-center build-out. Fiscal 2026 revenue reached 67.4 billion USD and remaining performance obligations hit 638 billion USD, but capex of 55.7 billion USD drove free cash flow to negative 23.7 billion USD, and S&P cut the credit rating to BBB- in July. Rating Hold: the 34% fall from the previous report's 181 USD reference point has absorbed much of the financing anxiety, but at 119.90 USD there is still no meaningful margin of safety for new money.
49/100
Tesla: The Franchise Is Real, but $900 Billion of the Market Cap Rests on Robotaxi Economics No One Has Disclosed
Tesla is an integrated EV and battery-storage manufacturer whose trailing-twelve-month revenue now exceeds $100 billion, and it is redirecting that industrial base to fund robotaxis, AI infrastructure and humanoid robots. Q2 2026 revenue rose 26% to $28.236 billion while operating income fell 57% to $398 million, operating margin dropped to 1.4%, capex jumped 142% to $5.789 billion and free cash flow swung to negative $1.092 billion, with 2026 capex now guided above $25 billion. Rating Watch: the visible auto, energy and charging businesses are worth roughly $140 to $190 billion against a $1.095 trillion market cap, which leaves about $905 to $955 billion of the price resting on robotaxi and Optimus economics the company has not disclosed.
61/100
Figma: The Platform Role Is Real, but Dilution and the Last Unlock Leave No Margin of Safety
Figma is a browser-native collaborative design platform that monetizes Full, Dev, and Collab seats across Professional, Organization, and Enterprise plans, with governance add-ons and, since March 2026, paid AI credits layered on top. Q1 2026 revenue rose 46% to $333.4 million and net dollar retention reached 139%, yet GAAP gross margin fell to 79% from 91% a year earlier as AI hosting costs jumped, and roughly $1.96 billion of unrecognized stock-based compensation still sits on the books. Rating Watch: the platform role looks more durable than the market's AI-obsolescence narrative implies, but dilution, margin pressure, and a final 77.7 million-share lock-up release leave no margin of safety at $22.94.
35/100
JOINN Laboratories (China) Co., Ltd.
JOINN Laboratories is China's largest listed non-clinical CRO, running GLP toxicology and drug-safety studies while owning a herd of more than 20,000 research primates carried on the balance sheet at fair value. Reported earnings are now driven by that biological-asset line rather than by service margins: H1 2026 guidance puts attributable net profit at RMB 600.1 million to RMB 900.2 million on revenue of only RMB 668.6 million to RMB 739.0 million, with macaque revaluation contributing RMB 703 million to RMB 777 million while laboratory services swing between a RMB 142 million loss and a RMB 65 million profit. Rating Avoid: at CNY 49.70 the A-share trades near 75x trailing earnings and at roughly a 130% premium to its own H-share, capitalizing a cyclical accounting gain as if it were durable service profit.
43/100
RPM International Inc.
RPM International is a decentralized holding company built around specialty coatings, sealants and construction chemicals, selling repair, restoration and protective-coatings brands like Rust-Oleum, DAP, Tremco, and Stonhard to a $7.86 billion fiscal 2026 revenue base. A multi-year MAP 2025 operating program has held gross margin flat through an inflationary stretch and lifted cash conversion, but at roughly 20.6 times trailing earnings the stock already prices in most of that self-help progress just as fiscal 2027 opens with fresh raw-material and tariff inflation. Rating Hold: a genuinely improving quality business, but with a thin margin of safety until the next cost cycle proves manageable.
31/100
Jianghua Micro: A Real but Mixed Wet-Chemicals Business Priced Like a Pure Semiconductor-Materials Platform
Jiangyin Jianghua Microelectronics is a wet electronic chemicals maker selling ultra-pure reagents and photoresist-supporting chemicals across semiconductor, display, and solar customers, with semiconductor now the largest end market at about CNY 711 million of 2025 revenue. The stock trades as if this were already a pure semiconductor-materials platform, but 2025 revenue rose only 12.3% and net profit 6.3% while the shares changed hands around 116x trailing earnings, well above stronger or more focused domestic peers Shanghai Sinyang (83x), Anji Micro (71x), and Greenda (63x). Research rating Avoid: real domestic-substitution progress and improving mix are being capitalized at a multiple that already assumes years of successful fab penetration the company has not yet delivered.
43/100
Envista Holdings Corporation
Envista Holdings is a diversified dental-products company built from Danaher's former dental segment, selling implants, orthodontics, imaging, and consumables across a $2.72 billion revenue base. A 2023-2024 stretch of guidance cuts and a $1.15 billion goodwill impairment gave way to a broad recovery: four straight quarters of positive core growth and expanding margins, with 2026 guidance reaffirmed, but the current price near $26 already credits much of that repair, leaving only a thin owner-earnings yield above risk-free Treasury bonds. Rating Hold: genuine operational improvement, but limited margin of safety until the recovery proves durable through tougher comparisons.
42/100
Shanghai Sinyang Semiconductor Materials: A Real Domestic-Substitution Winner, but Today's Price Already Discounts Years of Fab Penetration
Shanghai Sinyang is a China A-share semiconductor materials supplier that has pivoted from a legacy specialty-coatings business into a domestic-substitution winner across electroplating, cleaning, etching, photoresist, and CMP wet-process chemicals for wafer fabs. 2025 semiconductor revenue reached CNY 1.517 billion, up 46.5% year over year, and the company now describes itself as a baseline-qualified supplier on 66 domestic 12-inch and 25 8-inch production lines, with net profit up 71% and operating cash flow more than doubling, though the stock already trades around 90 times trailing earnings against a CNY 38-43 fair-value range. Rating Hold: a real domestic-substitution winner, but today's price already discounts several more years of successful fab penetration and margin retention.
43/100
XPeng: A Genuine Margin Recovery, But the Stock No Longer Prices Like a Distressed Turnaround
XPeng Inc. (XPEV.US) is a Guangzhou-based smart-EV maker whose 2025 recovery delivered RMB76.72 billion in revenue, an 18.9% gross margin, and its first-ever quarterly profit, before Q1 2026 revenue fell 17.6% year over year to a RMB1.78 billion loss even as gross margin held at 20.6%. The bull case rests on a reusable ADAS and Turing-chip software stack now extending into robotaxi, robotics and flying-car projects; the bear case is that China's EV price war remains brutal and these 'physical AI' bets could absorb management focus well before they generate returns. Rating Hold: the car business has genuinely improved, but at $12.33 the stock already sits inside the report's own acceptable-hold band, leaving little margin of safety beyond steady execution.
38/100
Kawasaki Heavy Industries: Aerospace Earned the Rerating, the Rest of the Group Still Has to Pay for It
Kawasaki Heavy Industries is a Japanese heavy-industrial conglomerate spanning aerospace and defense, energy and marine engineering, rolling stock, and robotics, with FY2025 revenue of ¥2,311.3 billion. Aerospace Systems has become the group's largest profit pool as Japan's defense build-up accelerates, with Ministry of Defense sales reaching ¥429.8 billion, but the July 2026 issuance of new shares and convertible bonds to fund aircraft engines, robotics and hydrogen projects dropped the stock roughly 7% and underscored how capital-hungry the rest of the group remains. Rating Hold: the aerospace-led rerating is real, but thin Rolling Stock margins, unproven hydrogen economics and fresh dilution leave today's price near fair value rather than a compelling entry point.
40/100
Shanghai Junshi Biosciences: A Real PD-1 Franchise, But the A-Shares Already Price an Unproven Profit Bridge
Shanghai Junshi Biosciences (688180.SHG) is a Chinese biopharma whose PD-1 antibody toripalimab now drives about 83% of group revenue, with 2025 revenue up 28.2% and Q1 2026 operating cash flow turning positive for the first time. The stock trades at roughly a 125% premium over its Hong Kong-listed H-shares (1877.HK) because Shanghai investors are pricing a bridge to durable, non-recurring-free profitability that management has not yet finished building. Rating Hold: commercial execution is improving fast, but the current A-share price already discounts much of that bridge, leaving little margin of safety.
40/100
Shanghai MicroPort MedBot: Commercial Traction Is Real, but the Re-Rating Has Already Happened
Shanghai MicroPort MedBot is a Chinese surgical-robotics developer whose Toumai laparoscopic platform and SkyWalker orthopedic robot have moved from clinical-trial promise into real commercial installations across more than 60 countries. FY2025 revenue rose 114.2% to RMB551.1 million with gross margin improving to 48.4% and free cash outflow shrinking sharply, and the company just guided to first-half 2026 profitability, but roughly 71% of 2025 revenue still ran through related-party sales with parent MicroPort and the stock already trades near 32 times trailing sales. Rating Hold: the commercial inflection is genuine, but at HK$20.22 the market has already re-rated the stock to price in much of that transition, leaving little margin of safety against any execution slip.
38/100
Rocket Pharmaceuticals: Cash Buys Time, but Danon Still Has to Earn Back the Market's Trust
Rocket Pharmaceuticals (RCKT.US) is a rare-disease gene-therapy developer whose sole approved product, Kresladi, still generates no revenue, leaving cash and a $180 million voucher sale as the real near-term story. The stock trades near the value of its cash alone because the market still distrusts the pivotal Danon cardiac program after a 2025 clinical hold, even though Phase 1 data and a modified lower-dose cohort keep the thesis alive. Rating Hold: cash buys time, but Danon still has to earn back trust and Kresladi is too small to carry the valuation on its own.
44/100
Jiangsu Hengli Hydraulic: A Real Compounder, but a Stock Already Pricing an Unproven Robot Story
Jiangsu Hengli Hydraulic (601100.SHG) is China's dominant hydraulic-components maker, still earning most of its profit from excavator cylinders, pumps and valves while building an early, largely undisclosed linear-motion and humanoid-robot-actuator business. 2025 revenue grew 16.5% and 2026 Q1 accelerated further, but cash conversion deteriorated sharply and the robot narrative still lacks separately disclosed revenue, backlog, or named customers. Rating Hold: a real hydraulics compounder trading inside its own fair-value band, with little margin of safety once optimism about the unproven robot story is priced in.
35/100
Absci Corporation: The Platform Is Real, but the Price Already Bets Big on ABS-201
Absci is a clinical-stage biotech that uses generative AI, proprietary high-throughput lab data, and wet-lab validation cycles to design antibodies, but current revenue still comes almost entirely from small, lumpy partnered discovery fees rather than owned products. FY2025 revenue was just $2.8 million and fell further to $0.2 million in Q1 2026, while the June 2026 announcement of positive interim Phase 1 safety data for lead asset ABS-201 (androgenetic alopecia) let the company raise $100 million, including a $40 million allocation from Eli Lilly, at $7.41 a share. Rating Hold: the platform and early clinical data are genuinely more credible than a year ago, but at $7.56 the stock already sits near a roughly $1.2-1.3 billion valuation on almost no current revenue, leaving little room for anything short of a strong ABS-201 efficacy readout.
41/100
Fujikura: A Real AI-Optics Profit Engine, but a Price That Leaves No Margin of Safety
Fujikura is a century-old Japanese cable manufacturer whose profit mix is now dominated by AI-datacenter optical fiber and cable, with the Information & Telecommunications segment producing 55% of FY2026 revenue and 81% of operating profit. FY2026 sales rose 20.7% to JPY 1,182.4 billion and operating profit 39.2% to a record JPY 188.7 billion, and a sharp June 2026 guidance revision (to JPY 1.462 trillion sales and JPY 310 billion operating profit for FY2027) pulled the company's own FY2028 mid-term target nearly into reach a year early, yet the roughly JPY 8.15 trillion market cap already exceeds Sumitomo Electric's despite a fraction of its revenue. Rating Watch: the AI-optics earnings are real and accelerating, but at JPY 4,593 the stock trades far above the report's conservative fair-value band of JPY 2,400-2,800, leaving no margin of safety.
43/100
Beijing Geekplus Technology: The AMR Core Is Real, the Humanoid Story Is Still Optionality
Beijing Geekplus Technology is a Beijing-founded, Hong Kong-listed warehouse-automation company that sells autonomous mobile robot (AMR) systems for warehouse fulfilment and industrial material handling, with 75.3% of 2025 revenue coming from outside mainland China. FY2025 revenue grew 31.6% to RMB3.171 billion, gross margin improved to 35.5%, and the company posted its first adjusted net profit of RMB43.8 million and positive operating cash flow of RMB85.7 million, even as statutory net income stayed negative RMB10.4 million and trade receivables grew faster than revenue. Rating Hold: the core AMR business is a proven, globally exportable operating model, but at HK$9.81 the stock still prices in more margin durability than the company has fully demonstrated, while the newer humanoid and embodied-intelligence narrative remains optionality rather than disclosed revenue.
43/100
Shenzhen Dobot: Real Cobot Business, Unproven Humanoid Bet
Shenzhen Dobot is a Hong Kong-listed collaborative-robot maker using its established industrial-automation business to fund a fast-growing but still small embodied-intelligence push into humanoids and quadrupeds. 2025 revenue grew 31.7% to RMB492.2 million with a narrowing net loss, but embodied-intelligence products were only about 4% of main-business revenue with margin slipping to 43.4% from 49.9%, while the company diluted shareholders twice in 2025 and is now pursuing a ChiNext A-share listing for further capital. Rating Hold: at HK$25.22 the stock sits near base-case fair value with no margin of safety against the conservative scenario, still pricing meaningful future execution rather than current profitability.
37/100
Furukawa Electric: A Real AI-Optics Transition the Market Has Already Priced In
Furukawa Electric is a diversified Japanese cable-and-electronics conglomerate whose profit mix is pivoting from legacy automotive-wire and metal businesses toward AI-datacenter optical cable, connectivity, and cooling products under its Lightera-branded optical unit. FY2025 sales reached JPY 1,307.6 billion with operating profit of JPY 63.9 billion, and FY2026 guidance calls for Optical Solutions and Digital Infrastructure Components operating profit to more than double, but FY2025 free cash flow was negative JPY 19.0 billion and the roughly JPY 2.48 trillion market cap already implies about 30 times FY2026 guided profit. Rating Watch: the datacenter-optics pivot is real and already visible in segment guidance, but at JPY 3,513 the stock trades well above the report's base-case fair value of JPY 2,100-2,800, leaving no margin of safety.
47/100
Yuanjie Semiconductor: Real AI-Optics Growth, Zero Margin of Safety
Yuanjie is an upstream IDM laser-chip maker whose product mix flipped from telecom toward AI-driven data-center silicon-photonics CW light sources, lifting 2025 revenue to CNY 601.4 million (gross margin to 58.15%) and driving 2026 H1 guidance up 339-364% year on year. But the same filings show its largest customer alone supplied 53.35% of 2025 sales (up from 16.38% in 2024), the CNY 1.251 billion phase-two expansion withholds its capacity target, and part of the H1 2026 profit surge is non-recurring fair-value gains. Rating Avoid: at CNY 1,445 the stock already prices in years of flawless scaling above even this report's own optimistic CNY 1,180/share fair-value estimate, with a margin-of-safety verdict of none.
36/100
Plug Power: A Real Turnaround With Zero Margin of Safety
Plug Power is a vertically integrated hydrogen platform selling fuel-cell systems, electrolyzers and hydrogen supply, still trying to prove that owning the whole stack creates value rather than just multiplying capital needs. FY2025 revenue reached about $710 million and gross margin turned positive for the first time in Q4 2025, but slid back to negative 13.2% in Q1 2026 while unrestricted cash fell from $368.5 million to a preliminary $162 million by June 30, keeping dilution risk from the ATM and Yorkville programs very much alive, and the DOE's $1.66 billion loan remains suspended rather than functioning as a funding backstop. Rating Watch: real operating progress, but at $2.19 the stock already sits above the report's own $1.25 conservative fair-value estimate with zero margin of safety.
34/100
Generate Biomedicines: The Asset Is Real, the AI Premium Is Still on Trial
Generate Biomedicines is a clinical-stage generative-biology company designing AI-generated protein therapeutics, funding its lead Phase 3 severe-asthma asset GB-0895 from Novartis and Amgen collaboration revenue and a post-IPO cash balance of $516.6 million as of March 2026. The core tension: Q1 2026 collaboration revenue fell to $7.2 million from $8.8 million a year earlier while net loss widened to $61.7 million and operating cash burn reached $80.4 million, so nearly all of the company's value now rests on one late-stage asset that will not complete enrollment until the first half of 2028, even as the stock still trades about 13% below its February 2026 IPO price. Rating Hold: the platform science and cash runway are real, but at $13.90 the market has already priced in a meaningful share of GB-0895's eventual success, leaving little margin of safety for new capital.
36/100
CGN Power: A Real Nuclear Moat, but No Margin of Safety Yet
CGN Power is China's listed nuclear-generation platform under China General Nuclear Power Group, operating 28 reactors with 31.838 GW of capacity at year-end 2025 and one of the industry's largest build-out pipelines, 18 units still under construction as of mid-2026. The core tension: 2025 revenue fell 4.1% to RMB 75.70 billion and Q1 2026 revenue dropped a further 13.25% as refuelling outages hit availability even as market-based tariffs fell about 8.8%, though half-year 2026 data show the decline sharply narrowing as Q2 generation recovered year on year. Rating Hold: a genuine state-backed nuclear moat with a real multi-year build-out runway, but at CNY 4.11 (about 22.5x trailing earnings) the A-shares already price in much of that story with no large margin of safety.
49/100
Rheinmetall: Respect Without Urgency for a Re-Rated Defence Prime
Rheinmetall is Germany's dominant defence prime, an ammunition-and-land-systems specialist riding a record €73.0bn backlog as European rearmament accelerates past €380bn in 2025 defence spending. FY2025 continuing sales rose to €9.94bn at an 18.5% margin, led by a 29.3% margin in the core Weapon and Ammunition unit, but June's abrupt cancellation of the F126 frigate programme wiped out nearly a fifth of the share price in a single day, exposing how much of the celebrated backlog is framework rather than firm order intake. Rating Hold: a genuinely stronger, cleaner defence business than it was two years ago, but a stock still priced at roughly 40x earnings for execution that has not yet been proven immune to political reversal.